Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,970 shares of the biopharmaceutical company’s stock after buying an additional 540 shares during the period. E. Ohman J or Asset Management AB’s holdings in Regeneron Pharmaceuticals were worth $3,540,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Centaurus Financial Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $118,000. Czech National Bank raised its holdings in shares of Regeneron Pharmaceuticals by 7.0% in the third quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock valued at $22,725,000 after buying an additional 1,405 shares during the last quarter. Park Avenue Securities LLC boosted its stake in shares of Regeneron Pharmaceuticals by 7.6% during the third quarter. Park Avenue Securities LLC now owns 1,889 shares of the biopharmaceutical company’s stock worth $1,986,000 after buying an additional 134 shares during the period. GAMMA Investing LLC grew its holdings in shares of Regeneron Pharmaceuticals by 32.6% during the third quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock worth $1,510,000 after buying an additional 353 shares during the last quarter. Finally, Miracle Mile Advisors LLC increased its position in Regeneron Pharmaceuticals by 12.6% in the 3rd quarter. Miracle Mile Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $2,693,000 after acquiring an additional 286 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.9 %

REGN stock opened at $666.85 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 12 month low of $663.43 and a 12 month high of $1,211.20. The firm has a market capitalization of $73.28 billion, a PE ratio of 16.50, a P/E/G ratio of 1.60 and a beta of 0.08. The company’s 50 day simple moving average is $720.81 and its 200-day simple moving average is $921.72.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.53%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on REGN. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.